ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for IMUC
+0.0022 (2.31%)
Oct 21 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.09 - 0.10
52 week 0.08 - 0.53
Open 0.10
Vol / Avg. 896,777.00/1.62M
Mkt cap 13.56M
P/E     -
Div/yield     -
EPS -0.21
Shares 137.80M
Beta 0.66
Inst. own 9%
Nov 14, 2016
ImmunoCellular Therapeutics Ltd Extraordinary Shareholders Meeting - 9:00AM EST - Add to calendar
Nov 8, 2016
Q3 2016 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 22, 2016
Q2 2016 ImmunoCellular Therapeutics Ltd Earnings Call - Webcast
Aug 22, 2016
Q2 2016 ImmunoCellular Therapeutics Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -97.26% -46.29%
Return on average equity -150.48% -56.83%
Employees 6 -
CDP Score - -


23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Officers and directors

Andrew Gengos President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 62
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
John S. Yu M.D. Director
Age: 51
Bio & Compensation  - Reuters
Anthony Gregg Lapointe CPA Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Independent Director
Age: 54
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 55
Bio & Compensation  - Reuters